  |
||||||
|
||||||
| |||||||||
Supplementary Material
Supplements to: Bach PB. Limits on Medicare’s Ability to Control Rising Spending on Cancer Drugs. N Engl J Med 2009;360:626-33. DOI: 10.1056/NEJMhpr0807774.
Download the Supplementary Appendix (PDF).
(PDF updated February 5, 2009.)
This appendix has been provided by the author to give readers additional information about his work.
This file is in Adobe Acrobat (PDF) format. If you have not installed and configured Acrobat Reader on your system, click here for instructions.
 View Interactive Graphic |
Interactive Graphic. Monthly and Median Costs of Cancer Drugs at the Time of Approval by the Food and Drug Administration (FDA), from 1965 through 2008.
Shown are costs for 1 month of cancer treatment for a person who weighs 70 kg or has a body-surface area of 1.7 m2. The red line indicates median prices during a 5-year period. Prices have been adjusted to 2007 dollars and reflect the total price for the drug at the time of approval, including both the amount of Medicare reimbursement and the amount paid by the patient or by a secondary payer. (Graphic updated February 5, 2009.) |
| This file is in Flash (SWF) format. If you do not have the latest version of Flash Player, download it at www.macromedia.com. If you still cannot view the file or have other questions, you may webmaster{at}nejm.org. | |
| |||||||||
HOME | SUBSCRIBE | SEARCH | CURRENT ISSUE | PAST ISSUES | COLLECTIONS | PRIVACY | TERMS OF USE | HELP | beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved. |
